Gastric-GEJ Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Due to their location between the oesophagus and the stomach, GEJ cancers have historically been categorized as either oesophageal or gastric tumours, which has generated controversy and disagreement about this classification. The incidence of GEJ tumors has significantly increased in Western populations, and distal oesophageal cancer is the most prevalent form of esophageal cancer in the USA. Similar to this, rates of distal gastric cancer have decreased while those of proximal gastric cancer have increased. Several surgical techniques can be used to treat GEJ cancers. Instances include esophagectomy combined with partial gastrectomy and extended total gastrectomy with or without thoracotomy.

Description

Due to their position between the oesophagus and the stomach, GEJ cancers have historically been categorized as either oesophageal or gastric tumours, which has generated controversy and disagreement about this classification. GEJ tumours are also known by the names distal oesophageal cancers, proximal gastric cancers, and cancers of the cardia. According to the study, this has led to differences in the prognosis, surgical approach, pathogenesis, and categorization. The most common definition for GEJ cancer is that it is a cancer. As a result of their work, the tumours were given their own classification and were separated from gastric or oesophageal malignancies. He proposed classifying GEJ tumors according to whether the cancer's epicentre is 5 cm away from or close to the Z-line. Similar guidelines have been adopted by the Union for International Cancer Control (UICC), which recommends that tumors with oesophageal extension be staged and classified using an oesophageal scheme, while those without oesophageal extension should be staged using the gastric cancer scheme, even if they are located within 5 cm of the GEJ. The American Joint Committee on Cancer (AJCC) advises staging GEJ cancers with epicentres less than 2 cm from the cardia (Siewert Type I/II) as oesophageal tumors and staging GEJ cancers with epicentres farther than 2 cm from the cardia as gastric cancers.

Gastric-GEJ Cancer (Epidemiology)

The incidence of GEJ tumors has significantly increased in Western populations, and distal oesophageal cancer is the most prevalent form of esophageal cancer in the USA. In a similar vein, rates of proximal and distal gastric cancer have changed, with proximal rates increasing. In the USA, the incidence of GEJ tumors has increased 4% to 10% yearly since 1976. Comparatively higher than in other Eastern centers like Japan and Korea, proximal gastric cancer, cancer of the cardia, and distal esophageal cancer accounted for roughly 30%-40% of total gastric carcinoma in Western countries and, curiously, in China. In 2018, the World Health Organization estimated that gastric cancer caused 783,000 fatalities globally. Around the world, there are significant regional differences in the incidence of this disease. The disease is most common in Asia and is least common in North America and Northern Europe (e. g. Japanese, Korean Republic, and Mongolian). The countries in western Asia with the highest death rates include Iran, Turkmenistan, and Kyrgyzstan. By Arnold et al. Data from 92 cancer registries in 34 countries representing 10 world regions, including high-incidence countries like Japan and low-incidence ones like Australia, were used to make the prediction that global incidence rates of gastric cancer will continue to decline in the majority of countries. By 2035, rare diseases will be defined as having six cases per 100,000 person-years or fewer in 16 of those 34 countries. The total number of new cases of gastric cancer is expected to increase in the majority of countries, though. New cases may be slightly on the rise in some countries, like Canada, Cyprus, South Korea, Slovakia, and Thailand, while slightly declining in others, like Bulgaria and Lithuania. Arnold and associates. In 15 of 34 nations, including Belarus, Chile, the Netherlands, Canada, and the United Kingdom, predicted rises in incidence among those under 50 years old. Although incidence rates were consistently declining or remaining stable in those 50 years of age and older, Arnold et al. predicted rises in incidence among those under 50. According to the American Cancer Society, there will be about 26,560 new cases of stomach cancer in 2021 (16,160 men and 10,400 women). The average patient is 68 years old when they receive a diagnosis. Gastric cancer is the fifteenth most common cancer in the US. GEJ as well as esophageal cancer incidence have both seen a sharp increase, according to numerous population-based studies from Western countries.

Gastric-GEJ Cancer -Current Market Size & Forecast Trends

The market for gastric and gastroesophageal junction (GEJ) cancer is projected to experience robust growth, with the global market valued at approximately USD 6.73 billion in 2023 and expected to reach around USD 14.48 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.27% during this period. Key drivers of this growth include increasing incidence rates, advancements in treatment options such as immunotherapies and targeted therapies, and the introduction of new drugs like Opdivo and Keytruda into first-line settings. The rising prevalence of risk factors such as obesity, tobacco use, and dietary changes further contributes to market expansion. North America is expected to dominate the market due to its advanced healthcare infrastructure, while regions like Asia-Pacific are likely to see rapid growth due to higher incidence rates and improving healthcare access. Overall, the gastric and GEJ cancer market is well-positioned for significant expansion through 2035 as new therapies and diagnostic technologies continue to emerge.

There are various surgical methods for the treatment of GEJ cancers. Examples include esophageal resection with partial gastrectomy and extended total gastrectomy with or without thoracotomy. The goal of performing a radical lymphadenectomy with negative margins for resectable GEJ tumors requires that the surgical plan be tailored to the patient's needs and that sound oncological principles be followed. Surgery combined with chemotherapy and/or radiation is the standard of care for treating locally advanced esophageal cancer. Chemotherapy continues to be the main method of treatment for metastatic disease when compared to the best supportive care. Nevertheless, the prognosis for patients with GEJ cancers, which are treated according to the same paradigms as esophageal and gastric carcinomas, is still dismal because of the emergence of chemoresistance and the scarcity of efficient targeted therapies, like those that focus on the HER2 and vascular endothelial growth factor pathways. Immune checkpoint inhibitors have been examined in the context of chemoresistance to demonstrate the efficacy of immunotherapy for esophagogastric cancer. Current immunotherapeutic approaches are being evaluated in both the locally advanced and the metastatic settings.

Report Highlights

Gastric-GEJ Cancer - Current Market Trends

Gastric-GEJ Cancer - Current & Forecasted Cases across the G8 Countries

Gastric-GEJ Cancer - Market Opportunities and Sales Potential for Agents

Gastric-GEJ Cancer - Patient-based Market Forecast to 2035

Gastric-GEJ Cancer - Untapped Business Opportunities

Gastric-GEJ Cancer - Product Positioning Vis-a-vis Competitors' Products

Gastric-GEJ Cancer - KOLs Insight